Evaluation of lomustine as a rescue agent for cats with resistant lymphoma

Dutelle, Autumn L; Bulman-Fleming, Julie; Lewis, Craig A; Rosenberg, Mona P.

doi:10.1177/1098612x12448017

Cited by 26 publications

(52 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lower body weight has been previously shown to be associated with a poorer prognosis in a number of conditions. [24][25][26] Unfortunately, the BCS was not available for a large number of the cats in the current study, so it is difficult to identify whether it was the thinner cats that had the poorer prognosis or just those with a smaller stature. The explanation for why certain disease processes were associated with a poorer prognosis is less apparent.…”

Section: Discussionmentioning

confidence: 96%

“…Those with a lower body weight had an increased odds ratio of dying of their disease. Lower body weight has been previously shown to be associated with a poorer prognosis in a number of conditions . Unfortunately, the BCS was not available for a large number of the cats in the current study, so it is difficult to identify whether it was the thinner cats that had the poorer prognosis or just those with a smaller stature.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Esophageal feeding tube placement and the associated complications in 248 cats

Breheny

Boag

Gal

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Esophageal feeding tubes are commonly used to provide enteral nutrition to cats, but their use is associated with adverse effects. Objectives To evaluate the complications associated with e‐tube placement in cats and to identify factors predisposing to these complications. Animals Cats that had an esophageal feeding tube placed (n = 248). Methods This was a retrospective case review in which clinical records were interrogated across 2 referral centers to identify records of cats that had esophageal tubes placed. Clinical data were collected for signalment, clinical indication, method of placement, time of removal, and any complications. Logistic regression was then employed to assess the odds of an increase in complications, including infection and death. Results For those cats that survived to discharge, tubes were in place for a median of 11 days, ranging from 1 to 93 days. Complications occurred in 35.8% of the cats, with the most common being tube dislodgement (14.5%), followed by stoma site infections (12.1%). Cats receiving glucocorticoids or oncolytic agents (OR = 3.91; 95% CI, 1.14‐13.44) and with discharge at the stoma site (OR = 159.8; CI, 18.9‐1351) were at an increased odds of developing a stoma site infection, whereas those with a lower weight (OR = 1.33; 95% CI, 1.02‐1.75) or (pancreatic [OR = 4.33; 95% CI, 1.02‐18.47], neoplastic [OR = 15.44; 95% CI, 3.67‐65.07], respiratory [OR = 19.66; 95% CI, 2.81‐137.48], urogenital [OR = 5.78; 95% CI, 1.15‐28.99], and infectious diseases [OR = 11.57; 95% CI, 2.27‐58.94]) had an increased odds of death. The duration of time in place and the cat being discharged with the tube in place were not associated with an increased risk of infection or death. Conclusions and clinical importance Owners should be made aware of the potential risks involved and their predisposing factors.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Esophageal feeding tube placement and the associated complications in 248 cats

Breheny

Boag

Gal

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…), lomustine (Dutelle et al . ) and doxorubicin (Oberthaler et al . ) have been reported with progression‐free intervals and median survival times ranging from 169–241 days and 14.6 months respectively.…”

Section: Discussionmentioning

confidence: 99%

“…No exclusively small cell lymphoma cases were included in this study. Lomustine was found to markedly improve the median progression-free interval for cats with small to intermediate cell lymphoma over cats with large cell lymphoma (169 vs. 39 days) (Dutelle et al 2012). However, no studies have compared lomustine to cyclophosphamide or to reintroduction of chlorambucil and glucocorticoid to evaluate the effectiveness of these various rescue protocols in cats with small cell lymphoma.…”

Section: Introductionmentioning

confidence: 99%

Outcome and toxicity assessment of feline small cell lymphoma: 56 cases (2000–2010)

Pope

Tun

McNeill³

et al. 2015

Veterinary Medicine & Sci

View full text Add to dashboard Cite

Feline small cell lymphoma is associated with greater response to treatment and survival when compared to large cell lymphoma. Treatment‐associated toxicity, response to rescue chemotherapy and prognostic factors are largely unknown. This retrospective study was performed to identify treatment‐associated toxicity, response to rescue chemotherapy and treatment outcome for cats diagnosed with small cell lymphoma of various anatomic locations. Medical records from 56 cats were evaluated. All cats were treated with glucocorticoid and chlorambucil with discontinuation of treatment recommended at 1 year if complete clinical response was documented. Chemotherapy toxicity was uncommon (33.9%) and generally mild. Grade III or IV hepatotoxicity was documented in 10.7% of patients. Overall response rate was 85.7% with glucocorticoid and chlorambucil. Median progression‐free survival was 1078 days. Overall response rate for rescue chemotherapy was 59%. Reintroduction of prednisone and chlorambucil was associated with significantly longer survival than prednisone and lomustine (>1500 vs. 492 days, P = 0.01). Median overall survival times for cats with lymphoma of the gastrointestinal tract was not significantly different from those with extra‐intestinal disease locations (1148 vs. 1375 days, P = 0.23). Median overall survival was 1317 days. Toxicity, other than hepatotoxicity was mild. Rescue chemotherapy with re‐introduction of glucocorticoids and chlorambucil was most successful. Discontinuation of glucocorticoid and chlorambucil with subsequent reintroduction as rescue chemotherapy appears to be just as effective as continued administration in cats.

show abstract

“…La lomustina se recomienda en casos de linfoma cutáneo en gatos (3) y Komori et al (2) informaron una remisión completa en un gato con linfoma cutáneo de células T después del tratamiento. Sin embargo, Dutelle et al (16) encontraron resultados variables cuando la usaron como un agente de rescate para el linfoma en gatos, independientemente de la región anatómica afectada, los autores observaron mejores respuestas para el linfoma de pequeñas células que de grandes células. Ese estudio concuerda con la falta de respuesta observada en el linfoma de células grandes en este reporte.…”

Section: Discussionunclassified

Linfoma cutáneo tarsal en gato – estudio de caso

Viéra

Ferreira

et al. 2017

Rev MVZ Córdoba

View full text Add to dashboard Cite

Lymphoma is the most common lymphoproliferative disorder in cats. Cutaneous lymphoma, however, is a rare form of extranodal lymphoma. Recently, several cutaneous lymphomas at the tarsal region have been reported in cats. As it differs clinically and histopathologically from the common cutaneous lymphoma, it was denominated cutaneous tarsal lymphoma. The present study describes the case of a 13-year-old male domestic longhair cat that presented with a subcutaneous mass, of 30-days evolution, at the tarsal region of the right pelvic limb. Histopathology analysis showed malignant neoplasia of round cells, morphologically suggestive of large cell lymphoma. Immunohistochemistry confirmed the diagnosis of B-immunoblastic lymphoma. Patient was treated with lomustine, and prednisolone with an overall survival time of 2.1 months. The aggressiveness of this feline lymphoma reinforces the need for further studies to understand better the disease progression and to establish improved therapeutic protocols that can increase survival time and improve quality of life of these patients.Keywords: Feline, lomustine, metastasis, neoplasm (Source: DeCS). RESUMENEl linfoma representa la enfermedad linfoproliferativa más frecuente en gatos. Sin embargo, el linfoma cutáneo es una rara forma de linfoma extranodal. Recientemente, el linfoma cutáneo se reportó localizado en el tarso. Tanto clínica como histopatologicamente, esta forma difiere de la forma cutánea típica, y se denominó linfoma tarsal felino. Este estudio describe el caso de un gato, doméstico de pelo largo, 13 años de edad con una masa subcutánea, de 30 días de evolución en la región tarsal del miembro pélvico derecho. La histopatologia reveló neoplasia de células redondas, sugestiva de linfoma de células grandes. La inmunohistoquímica confirmó el diagnóstico de linfoma imunoblástico de células B. El tratamiento realizado fue lomustina y prednisolona con tiempo de sobrevida de 2,1 meses. La agresividad de este linfoma, refuerza la necesidad de estudios para entender su curso y mejorar protocolos terapéuticos que incrementen tanto la sobrevida como la calidad de vida para estos pacientes.Palabras clave: Felino, lomustina, metástasis, neoplasia (Fuente: DeSC).

show abstract

Evaluation of lomustine as a rescue agent for cats with resistant lymphoma

Cited by 26 publications

References 19 publications

Esophageal feeding tube placement and the associated complications in 248 cats

Esophageal feeding tube placement and the associated complications in 248 cats

Outcome and toxicity assessment of feline small cell lymphoma: 56 cases (2000–2010)

Linfoma cutáneo tarsal en gato – estudio de caso

Contact Info

Product

Resources

About